SCHEMBL1031027

SCHEMBL1031027

O=C(O)C(CS)NCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CPA3 P15088 1/20 0.50
FOLH1 Q04609 1/20 0.50
MME P08473 4/20 0.49
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1109641 1.00 CPA3 (0.50) CPA3FOLH1MMEGAAMAPT
SCHEMBL515921 1.00 CPA3 (0.50) CPA3FOLH1MMEGAAMAPT
Hydrochloric Acid SCHEMBL28182328 0.98 CPA3 (0.49) CPA3FOLH1MMEGAAMAPT
Hydrochloric Acid SCHEMBL1927540 0.98 CPA3 (0.49) CPA3FOLH1MMEGAAMAPT
Hydrochloric Acid SCHEMBL1927541 0.98 CPA3 (0.49) CPA3FOLH1MMEGAAMAPT
Benzenemethanethiol SCHEMBL11584239 0.95 IDO1 (0.47) CPA3FOLH1MMEGAAMAPT
SCHEMBL5505220 0.91 MME (0.49) MMEGAA
Cysteine SCHEMBL1927883 0.91 PTGS1 (0.49) CPA3FOLH1MME
SCHEMBL14777396 0.86 MEN1 (0.46) CPA3FOLH1MME
SCHEMBL14935818 0.86 FOLH1 (0.46) CPA3FOLH1MMEGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-11-06 US claimed
US-12441765-B2 Peptides and medical uses thereof ANBITION S.R.L. (IT) 2025-10-14 US claimed
WO-2025094171-A1 SUPERHYDROPHOBIC COATING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2025-05-08 WO claimed
CN-119565651-A Modification method of Pd/C catalyst and application of Pd/C catalyst in hydrodehalogenation reaction 江苏扬农化工集团有限公司 2025-03-07 CN claimed
CN-112996528-B Peptides and medical uses thereof 安必圣有限责任公司 2025-01-07 CN claimed
CN-113015539-B Peptides and medical uses thereof 安必圣有限责任公司 2025-01-07 CN claimed
WO-2024233569-A2 METHODS AND COMPOSITIONS FOR REDUCING MALODOR TAXA TECHNOLOGIES, INC. (US) 2024-11-14 WO claimed
EP-3740586-B1 SCREENING METHOD FOR SUBSTANCES REDUCING MALODOURS FROM EMANATIONS FROM A DOG MARS INC (US) 2024-11-13 EP claimed
EP-4448544-A2 CARBONIC ANHYDRASE IX LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-10-23 EP claimed
US-12084709-B2 Screening method MARS, INCORPORATED (US) 2024-09-10 US claimed
US-20150175674-A1 LIPIDATED PEPTIDES AS ANTI-OBESITY AGENTS USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, v.v.i. (CZ) 2015-06-25 US claimed
EP-2872124-A2 LIPIDATED PEPTIDES AS ANTI-OBESITY AGENTS Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. (CZ) 2015-05-20 EP claimed
WO-2014134203-A9 AMPHIPHILIC DERIVATIVES OF THIOETHER CONTAINING BLOCK COPOLYPEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-23 WO claimed
WO-2014134203-A1 AMPHIPHILIC DERIVATIVES OF THIOETHER CONTAINING BLOCK COPOLYPEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-04 WO claimed
WO-2014118779-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-08-07 WO claimed
WO-2014009808-A2 LIPIDATED PEPTIDES AS ANTI-OBESITY AGENTS USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I (CZ) 2014-01-16 WO claimed
WO-2007087572-A2 AZA-PEPTIDE EPOXIDES GEORGIA TECH RESEARCH CORPORATION (US) 2007-08-02 WO claimed
WO-2004005270-A1 AZA-PEPTIDE EPOXIDES GEORGIA TECH RESEARCH CORPORATION (US) 2004-01-15 WO claimed
WO-1997016201-A1 ANGIOTENSIN IV AND ANALOGS AS REGULATORS OF FIBRINOLYSIS BRIGHAM & WOMEN'S HOSPITAL (US) 1997-05-09 WO claimed
WO-1995029691-A1 PROLINE PHOSPHONATE DERIVATIVES GEORGIA TECH RESEARCH CORPORATION (US) 1995-11-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441765-B2 Peptides and medical uses thereof FLT1, FLT4, TEK CPA3 200/4885FOLH1 267/4885MME 182/4885
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS CA9, CA13, CA4 CPA3 43/4885FOLH1 36/4885MME 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.